Research programme: proto-oncogene protein c-bcl-2 inhibitors - Servier
Alternative Names: S-44563Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Servier
- Class
- Mechanism of Action Apoptosis regulatory protein inhibitors; Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Uveal melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Uveal-melanoma in France
- 12 Nov 2011 Efficacy data from a preclinical trial in Uveal melanoma presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
- 15 Apr 2010 Preclinical trials in Uveal melanoma in France (unspecified route)